$iShares Genomics Immunology and Healthcare ETF(IDNA.US)

$SUNSHINE PHARMA(06887.HK)

Dongyangguang Pharmaceutical: A Traditional Giant Transforming into Cancer and Autoimmune Therapies

When screening global "Biopharma" companies, the FactSet index evaluates R&D pipelines and market capitalization. Because Dongyangguang Pharmaceutical has solid profits, healthy cash flow, and its new anti-cancer/immunology drug pipeline is gradually materializing, it is included in the index as a stable "Immuno Biopharma" component.

FactSet's AI crawler system scans global pharmaceutical companies based on "the number of patents and clinical filings related to R&D keywords (Immunology, Antibody)".

Dongyangguang Pharmaceutical scores extremely high on the "Immuno Biopharma" dimension, so the system automatically determines it meets the eligibility criteria for inclusion.

In recent years, they have invested heavily in R&D for monoclonal antibodies targeting autoimmune diseases (such as rheumatoid arthritis) and immune checkpoint inhibitors (PD-1/PD-L1) for solid tumors.